FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation In Children With Congenital Heart Disease
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation In Children With Congenital Heart Disease . (MENAFN - GlobeNewsWire - Nasdaq) Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108958021/FDA-Grants-Revascor-Rexlemestrocel-L-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-In-Children-With-Congenital-Heart-Disease
2024-12-04
rss
(MENAFN - GlobeNewsWire - Nasdaq) Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. ...
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation In Children With Congenital Heart Disease